Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521783 | 0.92 | TSHR (0.54) | EPHX2TSHRLMNAALDH1A1CA12 | |
| SCHEMBL2033309 | 0.85 | TSHR (0.54) | EPHX2TSHRLMNAALDH1A1RECQL | |
| SCHEMBL4520317 | 0.84 | CA12 (0.52) | EPHX2TSHRLMNAALDH1A1CA12 | |
| SCHEMBL6632846 | 0.83 | PRMT1 (0.35) | EPHX2TSHRLMNAALDH1A1 | |
| SCHEMBL14729453 | 0.83 | EPHX2 (0.52) | EPHX2CA12CA2CA9 | |
| SCHEMBL4103229 | 0.81 | EPHX2 (0.50) | EPHX2TSHRLMNAALDH1A1RECQL | |
| SCHEMBL4093088 | 0.79 | TSHR (0.52) | EPHX2TSHRLMNAALDH1A1RECQL | |
| SCHEMBL130413 | 0.79 | KDM4E (0.67) | EPHX2TSHRLMNAALDH1A1RECQL | |
| SCHEMBL9002644 | 0.79 | EPHX1 (0.64) | EPHX2TSHRLMNAALDH1A1RECQL | |
| SCHEMBL6014001 | 0.79 | EPHX1 (0.64) | EPHX2TSHRLMNAALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | EPHX2 4462/4885TSHR 573/4885LMNA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.